How the APOE4 gene and ketogenic diets affect the Alzheimer's brain
Investigating the combined role of APOE4 and ketogenic diets in Alzheimer's disease
This project explores whether the APOE4 gene changes how ketogenic diets and the ketone beta-hydroxybutyrate affect brain cholesterol, inflammation, and Alzheimer's risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11322757 on NIH RePORTER |
What this research studies
This work explores why people who carry the APOE4 gene often don't get the same benefits from ketogenic diets that help others. Researchers will use lab models that mimic ketogenic diets and human-derived brain cells to see how the main ketone, beta-hydroxybutyrate, moves into brain cells and changes cholesterol handling in glial (support) cells. They will look for signs that APOE4 causes cholesterol to build up inside support cells, triggers inflammation, and harms neurons, linking these molecular effects to Alzheimer's pathways. The team intends to connect these lab findings with clinical observations to clarify who may benefit from dietary or metabolic therapies.
Who could benefit from this research
Good fit: Ideal candidates are older adults concerned about Alzheimer's risk—especially people aged 65+ who know they carry the APOE4 gene or who have early cognitive concerns.
Not a fit: Younger people, individuals without Alzheimer's risk factors, or patients whose condition is unrelated to cholesterol or ketone metabolism may not get direct benefits from this research.
Why it matters
Potential benefit: If successful, this work could guide personalized diet advice or point to new treatments that prevent or slow Alzheimer's progression for people with different APOE types.
How similar studies have performed: Some clinical studies report cognitive improvements with ketogenic diets or ketone supplements in many older adults, but benefits are inconsistent and often absent in APOE4 carriers, making the mechanistic approach here relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Blanchard, Joel William — Icahn School of Medicine at Mount Sinai
- Study coordinator: Blanchard, Joel William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.